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Abstract
Acute lymphoblastic leukemia (ALL) is more frequent in children than in 
adults. The ALL is a hematological neoplasia, which is characterized by the hyper-
proliferation of lymphoid precursors in bone marrow. MicroRNAs (miRNAs) are 
a class of noncoding RNAs that regulate mRNA expression at posttranscriptional 
level. miRNAs regulate different biological processes such as development, 
proliferation, apoptosis, hematopoiesis, drug resistance, and tumorigenesis. It has 
also been observed that the expression of miRNAs can be used to the classification 
of the different subtypes of ALL. Likewise, miRNAs can also be used to determine 
the prognostic value and may represent potential therapeutic target molecules in 
the treatment of ALL.
Keywords: miRNAs, acute lymphoblastic leukemia, diagnosis, prognosis, therapy, 
biomarkers
1. Introduction
The hematopoiesis is primarily regulated at the transcriptional level by tran-
scription factors that act as master regulators of genes expression. However, the 
transcriptional process alone does not appear to control all aspects of cellular func-
tioning (cell fate, lineage, etc.), suggesting the participation of other mechanisms. 
The miRNAs constitute another critical way of hematopoietic regulation. The B- and 
T-lymphocytes develop from progenitor cells that occur in different organs; B-cell 
lymphopoiesis is completed in the bone marrow, whereas T-cell lymphopoiesis occurs 
in the thymus. However, their development and activation are controlled by signal-
ing pathways, which are also regulated by the microRNAs (miRNAs) [1]. miRNA 
expression profile during the normal and malignant hematopoiesis suggests that 
miRNAs are regulators of hematopoiesis implicated in regulating and maintenance 
of the “stemness” of the early progenitors, various stages of cell differentiation, and 
malignance [2].
Nowadays, there is evidence that miRNAs do not just regulate hematopoietic dif-
ferentiation and proliferation but also their activity. Deregulation of the expression 
of miRNAs has been observed in leukemias, and mechanistic studies reveal a role 
for miRNAs in the pathogenesis of this disorder [3].
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Leukemia is a clonal disorder in which the normal hematopoiesis is replaced by 
a malignant clonal expansion of immature hematopoietic cells (blasts) in the bone 
marrow or peripheral blood [4]. The first approach between miRNAs and leukemia 
was carried out by Calin et al. [5]. The author showed that the 13q14 deletion in 
B-cell chronic lymphocytic leukemias (B-CLLs) causes the loss of the precursor 
gene of miR-16-1 and miR-15a; therefore, the loss of these miRNAs is observed in 
approximately 70% of the CLLs [5]. Interestingly, it has been reported that at fragile 
sites, minimal regions of amplification (minimal amplicons), or common break-
point regions fragile sites, minimal regions of loss of heterozygosity, and genomic 
regions related with cancer code for approximately 50% of the miRNAs, hence the 
aberrant expression of different miRNAs in cancer [6].
The participation of miRNAs in different biological and cellular processes under 
pathological and normal conditions makes them good candidates in the investiga-
tion of functional markers for differential diagnosis, prognosis, and development 
of new therapeutic regimens, through the investigation of their molecular targets. 
In this chapter, the role of miRNAs expression profiles in ALL that could be used for 
classification of the disease establishing specific diagnoses and prognostic values 
is summarized. Likewise, the relation between the miRNA dysregulation and ALL 
may be a potential therapeutic target.
2. MiRNA biogenesis
The miRNA genes are transcribed by RNA polymerase II (Pol II) in the nucleus, 
and the primary miRNAs transcripts (pri-miRNAs) contain cap structures as well 
as poly(A) tails [7, 8]. The pri-miRNA transcript is processed by the microprocessor 
complex (Drosha/DGCR8), which crops the pri-miRNAs, producing a pre-miRNA 
Figure 1. 
miRNA biogenesis.
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(transcript of about 70 kb) [9–11]. The exportin 5 (XPO5) mediates the export 
of the pre-miRNAs from the nucleus to the cytoplasm [12–14]. In the cytosol, the 
pre-miRNA is recognized by Dicer enzyme (RNAse type III), producing a mature 
miRNA duplexes (miRNA:miRNA*) about 22 nucleotides [10]. The miRNA duplex 
binds to the RNA-induced silencing complex (RISC) [which is composed by of the 
transactivation-responsive RNA-binding protein (TRBP) and Argonaute2 (Ago2)] 
[8, 15]. The mature strand is retained by the Ago2 protein in the RISC complex, who 
directs the mature mRNA to its mRNA target for posttranscriptional gene silencing, 
while the complementary strand is degraded [16, 17] (Figure 1).
3. Functions of the miRNAs in lymphopoiesis
Lymphopoiesis is a process by which the hematopoietic stem cells (HSCs) 
differentiate into lymphoid progenitors and finally into B- or T-lymphocytes [18]. 
In the process of differentiation, the miRNAs play an important role. miR-29a and 
miR-196b are highly expressed by HSCs, and their downregulation is associated 
with differentiation into lymphoid progenitors [19, 20]. It has been reported that 
miR-17, miR-24, miR-155, miR-128, and miR-181 act to prevent the differentiation 
of early-stage progenitors [21].
miRNA-150 is expressed in both mature B- and T-cells. The lymphoid progeni-
tors express the miRNA-150 to give rise to the mature B-cells and assist in the 
transition from progenitor B-cell (pro-B) to the precursor B-cell (pre-B) stage [18]. 
And premature expression of miRNA-150 results in blocked transition from the 
pro-B-cell stage to the pre-B-cell stage [22, 23].
B-cell differentiation is regulated by the miR-155, and it has been observed that 
miR-155 levels are upregulated rapidly in both activated mature T- and B-cells [24]. 
Also, miRNA-155 regulates the differentiation of T-cells into Th type 1 cells [24, 25].
miR-181 is specifically expressed in hematopoietic cell, and its expression 
is dynamically regulated during early hematopoiesis and lineage commitment. 
miR-181 expression is high in the early B-cell differentiation stage and progressively 
decreases subsequently, and its ectopic expression in hematopoietic stem/progeni-
tor cells led to an increased fraction of B-lineage cells in both tissue culture differ-
entiation assays and adult mice [26]. Additionally, miR-181 also plays an important 
role in T-cell development [27].
The miRNA-15 family is an element required to promote the switch from 
pre-B-cell proliferation to a more differentiated stage. [28]. So, pre-B-cells lacking 
miRNA-15 family functions exhibit prolonged proliferation because of aberrant 
expression of the target genes cyclin E1 and D3, and they additionally fail to trigger 
the transcriptional reprogramming normal to their differentiation, resulting in a 
developmental block at the pre-B-cell stage [28].
Six miRNAs, miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and miR-92a-1 
are part of the miR-17-92 cluster; these small molecules are important for mature 
B-cell development. Absence of the cluster leads to the development of disorders in 
the maturation from pro-B to pre-B stage [29]. Ventura et al. using miR-17-92-de-
ficient mice found that B-cell development is inhibited at the pro-B to pre-B stage 
differentiation [30]. The above shows that if the miR-17-92 family miRNAs control 
the pro- to pre-B transition during B-cell development [31]. Likewise, it has been 
showed that in helper T cells, the miR-17–92a cluster is critical for the differentia-
tion from Th1 cells [32].
miR-29b is increased in Th1 cells, and the levels from this miRNA decrease sig-
nificantly upon T cell activation. So, the miR-29 expression can serve as a regulator 
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of Th1 differentiation [33]. Expression of miR-21 promotes Th2 differentiation in 
nonpolarized T cells [34]. miR-126 is another miRNA that also regulates the differ-
entiation of the Th2 cells [35].
4.  miRNA expression and its role in the differential diagnosis of acute 
lymphoblastic leukemia subtypes
Acute lymphoblastic leukemia (ALL) is characterized by clonal proliferation of 
early B- and T-lymphocyte progenitors that result in the accumulation of lympho-
blasts in the bone marrow and various extramedullary sites. ALL is also the hema-
tology neoplasia most commonly observed in the pediatric population, while it is 
relatively less common than AML in adults [36]. Around 75% of childhood ALL 
cases contain at least one alteration chromosomic, have lymphoid maturation arrest 
in distinct stages, and involve B- or T-lineages to leaving different immunopheno-
types with different miRNA signatures [37].
microRNAs participate in different physiological and cellular processes, such 
as development and tissue differentiation, cell identity, cell cycle progression, 
and programmed cell death [38]. Nowadays, it is known that the distinct stages of 
lymphopoiesis and the direction of lymphoid precursor maturation are influenced 
by miRNA expression differentially. However, an aberrant expression of miRNAs 
is related with malignant lymphopoiesis, characteristic that can be utilized as 
signature to diagnosis and classification diagnosis of acute lymphoblastic leukemia 
[18]. Interestingly, miRNA groups that can clearly differentiate ALL of its normal 
counterpart, B-ALL versus T-ALL and ALL subtypes with specific genetic abnor-
malities have been reported. De Oliveira and collaborators reported miRNA-128a 
and miRNA-181b overexpressed and miRNA-100, miRNA-196b, and let-7e with 
lower level when compared the miRNAs expression in normal pediatric bone 
morrow (BM) samples and BM samples of pediatric ALL. The authors point out 
miR-196b as a miRNA highly expressed in T-ALL, while miR-100 was related with 
the presence of t(12;21) [39].
A study in Brazilian children with T- or B-cell acute lymphoblastic leukemia 
(T-ALL or B-ALL) evaluated a bone marrow miRNAs profile that may be used 
for distinguishing childhood lymphoblastic leukemia subtypes [40]. The authors 
mention that miR-708-5p, miR-497-5p, miR-151a-5p, miR-151b, miR-371b-5p, miR-
455-5p, miR-195-5p, miR-1266-5p, miR-574-5p, miR-425-5p downregulated and 
miR-450b-5p, miR-450a-5p, miR-542-5p, miR-424-5p, miR-629-5p, miR-29c-5p 
upregulated in childhood T-ALL may be used for distinguishing childhood T- and 
B-ALL subtypes. However, a machine learning analysis showed that miR-29c-5p, 
which is involved in calcium signaling, is critical for B-cell lymphocyte fate. So, it is 
the best discriminator between childhood T- and B-ALL [40].
In a series of adult ALL cases, the expression profile of 470 miRNAs was measured 
by microarray analysis; 3 miRNAs (miR-148, miR-151, and miR-424) were identi-
fied as discriminative of T-lineage versus B-lineage ALL; and miR-151 dramatically 
downmodulated an miR-148a and miR-424 with higher expression in patients with 
T-ALL [41]. Furthermore, in the B-lineage ALL cases with special molecular lesions, 
those with BCR/ABL, E2A/PBX1, MLL/AF4 rearrangements and cases lacking 
known genetic abnormalities can be differentiated by a set of six miRNA, which was 
highlighted by one-way analysis of variance [41]. These miRNAs were preferentially 
expressed in each chromosomic rearrangement; miR-425-5p, miR-191, and miR-128 
were expressed in the E2A/PBX1-positive case, miR-629 was highly expressed in cases 
harboring MLL/AF4 rearrangement, while high levels of miR-146b and miR-126 were 
observed in the BCR/ABL-positive cases [41]. Other study in pediatric ALL showed 
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in seven major subtypes of pediatric ALL, which included: T-cell, MLL-rearranged, 
TEL-AML1-positive, E2A-PBX1-positive, hyperdiploid ALL, BCR-ABL-positive, and 
B-other ALLs, the differential miRNA expression. miRNA-708 was highly expressed 
in TEL-AML1, BCR-ABL, E2A-PBX1, hyperdiploid, and B-other cases than in the 
MLL-rearranged and T-ALL cases. On the other hand, the expression of miR-196b 
was higher in MLL-rearranged and T-ALL cases as compared with the expression level 
in the precursor B-ALL cases [42]. This information suggests that upregulated expres-
sion of miR-424 and downregulated expression of miR-151 might be good diagnostic 
markers to differentiate T-ALL regardless of age (Table 1).
Malik and collaborators propose a novel miR-2909-KLF4 molecular axis to 
differentiate the pathogeneses of pediatric B- and T-cell ALLs that may represent a 
new diagnostic marker, through alterations in miRNA expression patterns and their 
respective targets. The authors demonstrate the ability of miR-2909 to repress KLF4 
expression in pediatric B-ALL, but not T-ALL [43]. Another interesting work shows 
that miR-19b, miR-20a, miR-26a, miR-92, and miR-223 have cooperative effects 
on tumor suppressor genes implicated in the pathogenesis of T-ALL, including 
IKAROS, PTEN, BIM, PHF6, NF1, and FBXW7. Interestingly, these miRNAs are 
capable of promoting T-ALL development in a mouse model [44].
5. MicroRNAs as prognostic markers in ALL
MiRNAs are suggested as promising biomarkers not only in the diagnosis but 
also in the prognosis of ALL patients. Since they have been promising in identifying 
subgroups of patients with different clinical outcomes [45]. It has been observed 
that ectopic expression of miRNAs leads to the development of leukemia, such is 
the case of miR-125b, which has been reported in mice transplanted with fetal liver 
ALL subtype Upregulated expression Downregulated expression References
Children
T-ALL miR-450b-5p, miR-
450a-5p, miR-542-5p, 
miR-424-5p, miR-629-5p, 
miR-29c-5p
miR-708-5p, miR-497-5p, 
miR-151a-5p, miR-151b,
miR-371b-5p, miR-455-5p, 
miR-195-5p, miR-1266-5p, 
miR-574-5p, miR-425-5p
[39]
MLL-rearranged, T-ALL miR-196b [41]
TEL-AML1 BCR-
ABL, E2A-PBX1, 
hyperdiploid, and 
B-other
miRNA-708
Adults
T-ALL miR-148a,
miR-424
miR-151 [40]
E2A/PBX1-positive 
B-ALL
miR-425-5p, miR-191,
miR-128
MLL/AF4-positive 
B-ALL
miR-629
BCR/ABL-positive 
B-ALL
miR-146b,
miR-126
Table 1. 
Expression of miRNAs in children and adults to differentiate acute lymphoblastic leukemia subtypes.
Advances in Hematologic Malignancies
6
cells ectopically expressing miR-125b that showed an increase in white blood cell 
count, in particular in neutrophils and monocytes, associated with a macrocytic 
anemia. These mice developed B-cell acute lymphoblastic leukemia, T-cell acute 
lymphoblastic leukemia, or a myeloproliferative neoplasm, suggesting an important 
role for miR-125b in early hematopoiesis [46].
Patients group with high miR-21 expression was significantly associated with 
those aged <2 and > 10 years, lower platelets count, more incidence of central 
nervous system (CNS) infiltration, and poorer treatment outcome also; patients 
with high miR-21 showed a significantly poorer disease-free survival (DFS) and 
overall survival (OS) compared with those with low miR-21 expression group [47]. 
Also, miR-92a expression is significantly higher in ALL compared with peripheral 
blood mononuclear cells (PBMNCs) from healthy volunteers. Likewise, the expres-
sion levels of miR-99a, miR-100, and miR-128b correlated high-risk prognostic 
factors, including white blood cell (WBC) count, ALL subclassification (T-cell and 
B-cell ALL), the MLL-rearranged gene, and the BCR-ABL fusion gene, suggesting 
possible relation of miR-99a, miR-100, and miR-218b with prognosis [48, 49]. It has 
also been reported that mir-125b-2 is highly expressed in childhood ETV6/RUNX1 
(TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals 
independent of p53 [50].
More specifically, miR-9, miR-24, and miR-92a expression was significantly 
increased in a subset of ALL cells, and ALL patients with overexpressed miR-24 
and miR-92a had poor prognoses [51–53]. Wang et al. (2010) observed that miR-
146a, miR-181a/c, and miR-221 were significantly associated with overall survival 
of the ALL patients. Expression level of miR-146a and miR-181a/c was associated 
with a poor outcome (i.e., poor prognosis/short-term survival), whereas that of 
miR-221 was associated with a good outcome (i.e., good prognosis/long-term 
survival) [54], while that of miR-423-5p is associated with a poorer survival in 
patients with ALL [55]. Otherwise, the reduced expression of miR-155, miR-
181b, miR-182, miR-143, miR-210, and miR-335 is associated with poor outcome 
of pediatric ALL [56–60]. Also, the expression of miRNAs miR-18a, miR-532, 
miR-218, miR-625, miR-193a, miR-638, miR-550, and miR-633 is associated with 
early relapse in childhood ALL, suggesting possible relation of these miRNAs with 
prognosis [61].
The high miR-16 expression is associated with hyperleukocytosis and poor cyto-
genetic groups. In B-cell ALL patients, the DFS was significantly shorter in patients 
with high miR-16 levels. While in T-cell ALL patients, for both DFS and overall 
survival, a significant trend was found with a survival shortening from the lowest to 
the highest miR-16 levels [62, 63]. Likewise, it was reported that the expression of 
miR-16 was upregulated in cases of T lymphoblastic lymphoma/leukemia (T-LBL/
ALL), and the high expression group of miR-16 was significantly correlated with 
longer over survival [64].
For instance, Gimenes-Teixeira et al. reported that T-ALL patients with high 
miR-221 expression had significantly lower 5-year overall survival (OS) rates 
compared with those with low miR-221 expression [65]. Oliveira et al. observed that 
lower levels of miR-29a were significantly associated with higher blast counts in the 
bone marrow and with increased disease-free survival in T-ALL patients [66].
6.  miRNAs in response to commonly used chemotherapy agents in 
pediatric acute lymphoblastic leukemia
Despite the great effort of current treatment strategies, drug resistance still 
remains a major cause of chemotherapy failure and relapse in pediatric patients. 
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miRNAs have not only become tools for classifying subtypes of ALL and in 
support of the prognosis of this disease, but also studies have reported the clas-
sification of patients sensitive or resistant to drugs based on the expression of 
miRNAs.
Glucocorticoids (GCs) regulate proliferation, differentiation, metabolism, and 
cell survival in many tissues. In lymphocytes, they affect cell cycle progression, 
influence immunoglobulin and lymphokine production, and induce apoptosis in 
immature lymphoblasts [67]. Actually, these drugs are used clinically in the treat-
ment of childhood acute lymphoblastic leukemia (ALL) and other lymphoid malig-
nancies. In the group of glucocorticoids that is administered to patients with ALL is 
the prednisone; unfortunately, a proportion of patients are insensitive to this drug. 
A study in 49 ALL patients showed that miR-18a, miR-532, miR-218, miR-625, 
miR-193a, miR-638, miR-550, and miR-633 could distinguish prednisone-sensitive 
patients from prednisone-insensitive patients [68]. In contrast, other authors in a 
group of 81 children with newly diagnosed ALL, no discriminative microRNAs were 
found for prednisolone response [69].
It is well known that the presence of translocations in ALL is a frequent and 
prognostic influence event. In leukemia, MLL rearrangements are a common 
genetic alteration; MLL-AF4 acute lymphocytic leukemia (ALL), resulting from 
a balanced translocation between MLL and AF4, occurs in approximately 50% 
of ALL cases in infants, 2% in children, and 5–6% in adults. The poor prognosis 
of MLL-AF4 ALL to glucocorticoid-induced apoptosis is associated with its resis-
tance to this drug [70]. miR-128b and miR-221 are commonly downregulated 
in MLL-rearranged ALL compared with other types of ALL; also these miRNAs 
downregulate mRNAs encoding CDKN1B, MLL, AF4, and both MLL-AF4 and 
AF4-MLL fusion genes that are thought to contribute to leukemia development [71]. 
Interestingly, the restoration of miRNA-128b downregulates target genes including 
MLL, AF4, and both MLL-AF4 and AF4-MLL fusion oncogenes, and the restora-
tion of miRNA-221 downregulates CDKN1B cooperatively. Thus, the sensitivity 
of MLL-AF4 ALL cells to GCs is strengthened [71]. Study developed by Kotani 
et al. supports the idea that restoration of miRNA-128b improves the sensitivity 
of MLL-AF4 ALL cells to GCs. This author mentioned that one novel mutation of 
miRNA-128b significantly reduced its processing, and the resultant downregulation 
of mature miRNA-128b gave rise to GCs resistance due to the failure to downregu-
late the fusion oncogenes [72]. This suggests that miRNA-128b and miRNA-221 
could be GC (dexamethasone) sensitizers potential.
Other microRNAs related with drug resistance in pediatric acute lymphoblastic 
leukemia are miR-454, which present a low expression in L-asparaginase-resistant 
cases, whereas miR-125b, miR-99a, and miR-100 show an upregulation of their 
expression in patients resistant to vincristine and daunorubicin [69].
7. miRNAs as therapeutic targets in acute lymphoblastic leukemia
Nowadays, advances in our understanding of the molecular carcinogenesis of 
the human cancers and the extensive research on generate and implement new 
combined and targeted therapies, and have allowed to know specific molecular 
therapeutic targets. However, there is still a continuous need for development of 
new therapeutic tools for applicability.
RNA molecules actually are the therapeutic targets promising in the molecular 
oncology. The ability of miRNAs to regulate important cellular processes, by 
concurrently regulating multiple targets, their inherent role in carcinogenesis as 
oncogenes or tumor suppressor genes, and the aberrant dysregulation of their 
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expression levels in cancer, can represent a viable therapeutic strategy and a pow-
erful intervention tool in leukemia [73]. For example, in leukemia cells isolated 
from individuals with BCR/ABL, TKI-resistant Philadelphia-chromosome-positive 
acute lymphoblastic leukemia (Ph + ALL) was observed an increase in levels of 
DNMT3A in association with downregulation of miR-217; these observations are 
clinically relevant; and inhibition of DNMT3A by forced expression of miRNA-
217 may benefit in preventing drug resistance to TKI treatment in Philadelphia-
chromosome-positive ALL patients [74]. Another therapeutic strategy for 
BCR-ABL-positive ALL is miRNA-203, which has as direct target to BCR-ABL1 and 
ABL1, proteins with activity tyrosine kinase. This miRNA is silenced by genetic and 
epigenetic mechanisms in hematopoietic malignancies expressing either ABL1 or 
BCR-ABL1. However, the restoration of the miRNA-203 expression reduces ABL1 
and BCR-ABL1 levels and inhibits cell proliferation [75]. miRNA-143 was identified 
as a regulator of MLL-AF4 expression and is epigenetically repressed by promoter 
hypermethylation in MLL-AF4-positive primary blasts and cell lines;upregulation 
of miRNA-143 expression by demethylation has therapeutic promise for MLL-AF4 
B-cell ALL [76].
It is also important to consider that some miRNAs can behave as oncogenes in one 
cancer type and as tumor suppressive genes in others. It has been reported that miR-
221 maintains a high expression in hepatic cancer and exerts an oncogenic function 
by targeting tumor suppressor PTEN, but this miRNA acts as a tumor suppressor in 
erythroblastic leukemia by inhibiting the KIT oncogene expression [77, 78]. Thus, 
identification of specific biological functions, type of cancer, and targets of miRNAs 
is a basic aspect when considering miRNA therapeutics.
8. Summary and future directions
Various studies have demonstrated that the oncomiRs or tumor suppres-
sor miRNAs expression may significantly have potential how diagnostic and/
or prognostic biomarkers, as well as monitoring the disease progression and in 
the response to treatment, and it may be a therapeutic target for treatment in 
ALL. Also, miRNAs expression levels may play an important role in the genesis 
and evolution of the ALL. Nevertheless, the biological effects and relevant target 
genes of many miRNAs that are deregulated and/or prognostically relevant in 
ALL need to be identified and characterized. Therefore, novel anti-ALL agents are 
needed to overcome chemotherapy resistance and reduce cytotoxicity. The mim-
ics- and/or anti-miRNAs may be a good alternative. However, more experiments 
are required to evaluate the feasibility and safety of mimics- and/or anti-miRNAs 
in the clinical treatment.
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